Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

Phase 4 Completed 12 enrolled Baylor Research Institute International Urogynecological Association · collab The Methodist Hospital Research Institute · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Women presenting with overactive bladder symptoms will be randomized to one of 3 arms (anticholinergic, beta-3 agonist, placebo). They will undergo baseline cognitive testing, functional MRI of the brain. Cognitive testing and functional MRI will be repeated after taking their double blinded intervention for 30 days.

Timeline

Start: 2019-08-05
Primary completion: 2022-02-02
Completion: 2022-02-26

Publications

Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023 May 9;5(5):CD003781. doi: 10.1002/14651858.CD003781.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Mirabegron	Other / unclassified	25 mg	Oral
Comparator	Solifenacin	Small molecule	5 mg	Oral

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

Summary

Timeline

Publications

Drugs

Indications